What is the therapeutic implication of beclin-1 expression in high beclin-1 MCTs?

• A. Autophagy inhibitors (chloroquine, hydroxychloroquine) combined with current therapy may improve outcomes
• B. Higher dose of chemotherapy
• C. Radiation therapy alone is sufficient
• D. Beclin-1 inhibitors worsen outcomes

Answer: (A)

High Beclin-1 expression signals active autophagy, a process cancer cells can rely on to survive stress from therapy. Beclin-1 starts autophagy, so when tumors have high Beclin-1, they often use autophagy as a shield against treatment. Blocking this pathway with autophagy inhibitors such as chloroquine or hydroxychloroquine disrupts the autophagic process, making tumor cells less able to cope with chemotherapy or other therapies. Therefore, adding autophagy inhibitors to the current treatment regimen can enhance tumor cell death and potentially improve outcomes in high Beclin-1 MCTs. The other options don’t directly target the autophagy-driven survival mechanism that these tumors rely on, so they’re not as aligned with the biology of high Beclin-1 expression.